Dynavax Technologies Corporation (NASDAQ:DVAX) moved down -2.54% and closed its last trading session at $5.75. This Medical Sector stock currently has the Market Capitalization of 255.01 Million. The Average Volume for the stock is measured as 1.35 Million. The Stock has a 52-Week High of $23.62 and 52-Week Low of $3.2 following the dates, it touched its 52-Week High on Apr 19, 2016 and 52-Week Low on Nov 14, 2016. Currently, the Return on Assets value for the trailing twelve months is -74.2% with the Return on Equity and Return on Investment of -89.8% and -124.1% respectively. This firm currently has YTD (year to date) performance of 45.57 Percent which is awesome. The Short Ratio for the stock is 5.35.
Dynavax Technologies Corporation (NASDAQ:DVAX) Price to Earnings (P/E) ratio is 0. EPS or Earning per Share stands at $-2.92. The TTM operating margin is 0 percent.
Dynavax Technologies Corporation (NASDAQ:DVAX) reports its Earnings on Tue 14 Mar (5 days ago). The estimated EPS for the current quarter is said to be $-0.83. Following Earnings result, share price were DOWN 16 times out of last 28 Qtrs. The stock has reduced about -38.5% since it reported its last earnings. The Closing price of Dynavax Technologies Corporation (NASDAQ:DVAX) at Last Earnings was $6.25 as compared to the previous closing price of $5.75. The Predicted Move on the 7th day after Dynavax Technologies Corporation (NASDAQ:DVAX) will release its earnings at about 5%.
By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Dynavax Technologies Corporation (NASDAQ:DVAX) beats earnings by 41%, The Stock Missed Earnings 6 times and has met earnings 1 times.
We will discuss the past Quarters Earnings below:
On 03/06/2017, the stock reported the EPS of $-0.9 where Analysts were projecting the EPS to be $-0.75 showing a difference of $-0.15. Thus Surprise Factor was there with -20 percent. Before Earnings Announcement on 03/06/2017, the firm had its stock price of $6.25. And immediately on the next day after earnings announcement, the stock declined -4.8% and closed its trading session at $5.95. On 7th Day after earnings release, Dynavax Technologies Corporation (NASDAQ:DVAX) dropped to -5.6% from $6.25 to $5.9.
On 11/07/2016, Analysts were suspecting EPS of $-0.68/share where Dynavax Technologies Corporation (NASDAQ:DVAX) reported its Actual EPS of $-0.75. Thus showing a Surprise of -10.3 percent. The Closing Price of the stock before earnings was $9.75 while on the Next day the stock closed its trading session at $10.15 with a percentage change of 4.1% from the price of 9.75 before Earnings. The Stock Closing Price on the 7th day of earnings was $11.6.
Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the bodys innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. The companys lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for the treatment of for multiple malignancies, as well as DV281 for the treatment of non-small cell lung cancer. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for varios immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.